[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_102":103,"_104":57},"item-original",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":16,"_18":-5,"_19":-5,"_20":21,"_22":23,"_24":25,"_26":27,"_28":25,"_29":30,"_31":32,"_33":34,"_35":36,"_37":38,"_39":-5,"_38":40,"_41":-5,"_42":-5,"_43":-5,"_44":45,"_46":47,"_48":-5,"_49":50,"_51":52,"_53":54,"_55":36,"_56":57,"_58":-5,"_59":60,"_61":62,"_63":36,"_64":57,"_65":66},"id","p4fpu57uc7urmj76evns8igwh","revision",2,"title","#AACR26","originalTitle","summary","reason","source",{"_11":96,"_77":97,"_98":99,"_100":36,"_101":-5},"links",{"_93":94,"_66":95},"publishedAt","2026-04-20T00:25:21.000Z","discoveredAt","2026-10-22T11:08:32.613Z","timelineAt","category","opinion","tags",[],"score",60,"selected",false,"channel","x","story",{"_86":87,"_88":47,"_89":-5,"_90":-5,"_91":92},"insight","digest","conferenceAbstracts","readingMode","full","author","DrMirallas","language","body",{"_81":-5,"_66":82,"_83":84,"_85":57},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_75":76,"_77":78,"_79":-5,"_80":-5},"engagement",{"_67":68,"_69":70,"_71":72,"_73":74},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",16,"likes",9,"replies",1,"reposts",6,"slug","aacr-2026","name","AACR 2026 年会","topic","reading","zh","

#AACR26

Risvutatug rezetecan (B7H3-TOPI) + Abebrelimab (PD-1)
Dr. Zhong
ARTEMIS-101 (n=253)
NSCLC (ADK) no AGA
ORR 47.1%
mPFS 14m
14pts >12m
Bone marrow

Promising activity of #ADC and #ICI #NSCLC

@MLJohnsonMD2

@SarahCannonDocs
great

@OncoAlert

","zhKind","translation","complete","authorName","Oriol Mirallas MD","handle","avatarUrl","quoted","media",[],"aihot","/items/p4fpu57uc7urmj76evns8igwh","https://x.com/DrMirallas/status/2046022371455410203","aacr26-floor","AACR 2026 现场信号","kind","x_search","firstParty","iconUrl","changelogVersion","2026-10-23T01:25","enEditionEnabled"]